IceCure Medical stock jumps 12.12% in after-hours trading following strong 2024 ProSense sales growth and positive regulatory updates.

IceCure Medical surged 12.12% in after-hours trading following the release of its 2024 financial results, which highlighted a 42% growth in ProSense cryoablation sales in North America. The company also announced interim results from its ICESECRET kidney cancer study showing an 88.7% recurrence-free rate, and provided an update on its FDA engagement for ProSense in early-stage breast cancer. These developments signaled strong product adoption and regulatory progress, reinforcing investor confidence in the company’s growth trajectory and long-term potential.